Comments
Glenmark Pharmaceuticals USA has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.
These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.
“Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals Corp,” Glenmark said in a BSE filing.
As per IMS Health sales data for the 12-month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately $2.03 billion, it added.
Shares of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.